Literature DB >> 832662

Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

J W Paxton, F Rowell, J G Ratcliffe, D G Lambie, R Nanda, I D Melville, R H Johnson.   

Abstract

A simple, specific and rapid radioimmunoassay (RIA) method for the assessment of non-protein bound ('free') phenytoin (DPH) concentrations in mixed saliva is described. Epileptic patients on maintenance phenytoin therapy have mixed saliva phenytoin concentrations similar to 'free' drug levels measured directly in serum or cerebrospinal fluid (CSF), Salivary phenytoin levels are approximately 10% of the total serum level in treated epileptic patients and in normal subjects after ingestion of a single oral dose. The half time of disappearance of phenytoin after 100 or 300 mg doses is 12.2 +/- 3.0 (SD) h in serum and 12.3 +/- 3.2 (SD) h in saliva. This method of assessing the biologically active fraction of the drug may be particularly valuable in situations where serum protein binding is abnormal or in drug interactions. It is also non-invasive and requires small sample volumes (20mul) and may therefore be valuable in paediatric practice and in pharmacokinetic studies in which multiple venepunctures would otherwise be required.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832662     DOI: 10.1007/BF00561791

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

3.  Concentration of iodide, pertechnetate thiocyanate, and bromide in saliva from parotid, submandibular, and minor salivary glands in man.

Authors:  K W Stephen; J W Robertson; R M Harden; D M Chisholm
Journal:  J Lab Clin Med       Date:  1973-02

4.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

5.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

6.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

7.  Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures.

Authors:  L Lund
Journal:  Arch Neurol       Date:  1974-11

8.  Interaction of diphenylhydantoin (DPH) and tolbutamide in man.

Authors:  H Wesseling; I Mols-Thürkow
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

9.  Plasma albumin concentration and diphenylhydantoin binding in man.

Authors:  R J Porter; R B Layzer
Journal:  Arch Neurol       Date:  1975-05

10.  Effect of dosage increments on blood phenytoin concentrations.

Authors:  F Bochner; W D Hooper; J H Tyrer; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-12       Impact factor: 10.154

View more
  5 in total

1.  Aberrantly high phenytoin concentrations in saliva. Precaution in monitoring phenytoin concentrations in whole saliva.

Authors:  J W Paxton; S Foote
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

2.  Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.

Authors:  J W Paxton; B Whiting; K W Stephen
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 3.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

4.  Serum, tear and salivary concentrations of methotrexate in man.

Authors:  W H Steele; J F Stuart; B Whiting; J R Lawrence; K C Calman; J G McVie; G M Baird
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

5.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.